The PRESIDE (PhaRmacogEnomicS In DEpression) Trial: a double-blind randomised controlled trial of pharmacogenomic-informed prescribing of antidepressants on depression outcomes in patients with major depressive disorder in primary care

Saya, Sibel; Chondros, Patty; Abela, Anastasia; Mihalopolous, Cathrine; Chatterton, Mary Lou; Gunn, Jane; Chen, Timothy F.; Polasek, Thomas M.; Dettmann, Elise; Brooks, Rachel; King, Michelle; Spencer, Luke; Alphonse, Pavithran; Milton, Shakira; Ramsay, Georgia; Siviour, Zoe; Liew, Jamie; Ly, Philip; Thoenig, Matthew; Seychell, Raushaan; La Rocca, Floriana; Hesson, Luke B.; Mejias, Nydia; Sivertsen, Terri; Galea, Melanie Anne; Bousman, Chad; Emery, Jon

doi:10.1186/s13063-023-07361-6

Trials

Table 1 Algorithm for drug selection based upon concomitant medication-adjusted PGx phenotype in the preside

From: The PRESIDE (PhaRmacogEnomicS In DEpression) Trial: a double-blind randomised controlled trial of pharmacogenomic-informed prescribing of antidepressants on depression outcomes in patients with major depressive disorder in primary care

CYP2C19 phenotype	CYP2D6 phenotype	Citalopram [SSRI] *CYP2C19*	Desvenlafaxine [SNRI]	Duloxetine [SNRI]	Escitalopram [SSRI] *CYP2C19*	Fluoxetine [SSRI]	Fluvoxamine [SSRI] *CYP2D6*	Mirtazapine [others]	Paroxetine [SSRI] *CYP2D6*	Sertraline [SSRI] *CYP2C19*	Venlafaxine [SNRI] *CYP2D6*
Intermediate, normal or null	Intermediate	20 mg mane	50 mg mane	60 mg mane	10 mg mane	20 mg mane	50 mg nocte	15 mg nocte increase to	20 mg mane	50 mg mane	Not recommended
Poor	Intermediate	10 mg mane	50 mg mane	60 mg mane	5 mg mane	20 mg mane	50 mg nocte	30 mg nocte	20 mg mane	25 mg mane	Not recommended
Rapid or ultrarapid	Intermediate	Not recommended	50 mg mane	60 mg mane	Not recommended	20 mg mane	50 mg nocte	15 mg nocte increase to	20 mg mane	50 mg mane	Not recommended
Intermediate, normal or null	Normal	20 mg mane	50 mg mane	60 mg mane	10 mg mane	20 mg mane	50 mg nocte	30 mg nocte	20 mg mane	50 mg mane	75 mg mane
Poor	Normal	10 mg mane	50 mg mane	60 mg mane	5 mg mane	20 mg mane	50 mg nocte	15 mg nocte increase to	20 mg mane	25 mg mane	75 mg mane
Rapid or ultrarapid	Normal	Not recommended	50 mg mane	60 mg mane	Not recommended	20 mg mane	50 mg nocte	30 mg nocte	20 mg mane	50 mg mane	75 mg mane
Intermediate, normal or null	Null	20 mg mane	50 mg mane	60 mg mane	10 mg mane	20 mg mane	50 mg nocte	15 mg nocte increase to	20 mg mane	50 mg mane	75 mg mane
Poor	Null	10 mg mane	50 mg mane	60 mg mane	5 mg mane	20 mg mane	50 mg nocte	30 mg nocte	20 mg mane	25 mg mane	75 mg mane
Rapid or ultrarapid	Null	Not recommended	50 mg mane	60 mg mane	Not recommended	20 mg mane	50 mg nocte	15 mg nocte increase to	20 mg mane	50 mg mane	75 mg mane
Intermediate, normal or null	Poor	20 mg mane	50 mg mane	60 mg mane	10 mg mane	20 mg mane	25 mg nocte	30 mg nocte	10 mg mane	50 mg mane	Not recommended
Poor	Poor	10 mg mane	50 mg mane	60 mg mane	5 mg mane	20 mg mane	25 mg nocte	15 mg nocte increase to	10 mg mane	25 mg mane	Not recommended
Rapid or ultrarapid	Poor	Not recommended	50 mg mane	60 mg mane	Not recommended	20 mg mane	25 mg nocte	30 mg nocte	10 mg mane	50 mg mane	Not recommended
Intermediate, normal or null	Ultrarapid	20 mg mane	50 mg mane	60 mg mane	10 mg mane	20 mg mane	50 mg nocte	15 mg nocte increase to	Not recommended	50 mg mane	75 mg CR mane increase to 225 mg
Poor	Ultrarapid	10 mg mane	50 mg mane	60 mg mane	5 mg mane	20 mg mane	50 mg nocte	30 mg nocte	Not recommended	25 mg mane	75 mg CR mane increase to 225 mg
Rapid or ultrarapid	Ultrarapid	Not recommended	50 mg mane	60 mg mane	Not recommended	20 mg mane	50 mg nocte	15 mg nocte increase to	Not recommended	50 mg mane	75 mg CR mane increase to 225 mg

Back to article page

ISSN: 1745-6215

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com